SCHEMBL2882012

SCHEMBL2882012

CN(C)c1ncnc2ccc(/C=C3/SC(=N)NC3=O)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2A P48426 3/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 2/20 0.47
CLK1 P49759 5/20 0.47
DYRK1A Q13627 5/20 0.47
DYRK1B Q9Y463 4/20 0.47
PIK3CD O00329 4/20 0.47
CSNK2A2 P19784 4/20 0.47
PIK3CA P42336 4/20 0.47
PIK3CG P48736 4/20 0.47
CSNK2B P67870 3/20 0.47
CSNK2A1 P68400 3/20 0.47
DYRK2 Q92630 3/20 0.47
PIK3CB P42338 2/20 0.47
MTOR P42345 2/20 0.47
NPC1 O15118 1/20 0.47
MAOB P27338 1/20 0.47
RAB9A P51151 1/20 0.47
CISD1 Q9NZ45 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12975484 1.00 PIP4K2A (0.48) PIP4K2AMEN1KMT2APOLBCLK1
SCHEMBL2882014 1.00 PIP4K2A (0.48) PIP4K2AMEN1KMT2APOLBCLK1
SCHEMBL2882373 0.90 CISD1 (0.60) CLK1DYRK1ADYRK1BPIK3CDCSNK2A2
SCHEMBL2882375 0.90 CISD1 (0.60) CLK1DYRK1ADYRK1BPIK3CDCSNK2A2
SCHEMBL12975463 0.90 CISD1 (0.60) CLK1DYRK1ADYRK1BPIK3CDCSNK2A2
SCHEMBL496846 0.87 CRHBP (0.56) MEN1KMT2ACLK1DYRK1ADYRK1B
SCHEMBL10093409 0.87 CRHBP (0.56) MEN1KMT2ACLK1DYRK1ADYRK1B
SCHEMBL496844 0.87 CRHBP (0.56) MEN1KMT2ACLK1DYRK1ADYRK1B
SCHEMBL496986 0.85 DYRK3 (0.46) MEN1KMT2ACLK1DYRK1ADYRK1B
SCHEMBL496984 0.85 DYRK3 (0.46) MEN1KMT2ACLK1DYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 US claimed
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia MERCK SERONO SA (CH) 2009-02-12 US claimed
EP-1807075-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA Applied Research Systems ARS Holding N.V. (AN) 2007-07-18 EP claimed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 US claimed
WO-2006040318-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-04-20 WO claimed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 US claimed
EP-1549644-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-07-06 EP claimed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 WO claimed
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 US disclosed
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES LABORATOIRES SERONO S.A. (CH) 2009-12-10 US disclosed
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis LABORATORIES SERONO SA (CH) 2008-12-11 US disclosed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 US disclosed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 US disclosed
EP-1549644-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-07-06 EP disclosed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES ZAP70, BRCA1, ZYX PIP4K2A 873/4885MEN1 1495/4885KMT2A 3006/4885
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia PDPK1, PRKD3, PRKD1 PIP4K2A 215/4885MEN1 2366/4885KMT2A 1230/4885
US-20050222225-A1 Use of compounds for increasing spermatozoa motility CATSPER1, PI4KB, MAN2B2 PIP4K2A 12/4885MEN1 3768/4885KMT2A 2969/4885
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis PDPK1, PIK3R4, MAP3K3 PIP4K2A 78/4885MEN1 1758/4885KMT2A 603/4885
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives BRCA1, ZAP70, F13B PIP4K2A 830/4885MEN1 1543/4885KMT2A 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.